RESUMEN
BACKGROUND: Inflammatory myofibroblastic tumor (IMTs) are rare mesenchymal neoplasms with slow growth. Resection is considered as therapeutic standard, with chemotherapy being insufficiently effective in advanced disease. ALK translocations are present in 50% of cases, ROS1 fusions (YWHAE::ROS1, TFG::ROS1) are extremely rare. Here, we present a case with TFG::ROS1 fusion and highlight the significance of molecular tumor boards (MTBs) in clinical precision oncology for post-last-line therapy. CASE PRESENTATION: A 32-year-old woman presented with IMT diagnosed at age 27 for biopsy and treatment evaluation. Previous treatments included multiple resections and systemic therapy with vinblastine, cyclophosphamide, and methotrexate. A computed tomography scan showed extensive tumor infiltration of the psoas muscles and the posterior abdomen. Next generation sequencing revealed an actionable ROS1 fusion (TFG::ROS1) with breakpoints at exon 4/35 including the kinase domain and activating the RAS-pathway. TFG, the Trk-fused gene, exerts functions such as intracellular trafficking and exhibits high sequence homology between species. Based on single reports about efficacy of ROS1-targeting in ROS1 translocation positive IMTs the patient was started on crizotinib, an ATP-competitive small molecule c-MET, ALK and ROS1-inhibitor. With a follow-up of more than 9 months, the patient continues to show a profound response with major tumor regression, improved quality of life and no evidence for severe adverse events. CONCLUSION: This case underscores the importance of the availability of modern molecular diagnostics and interdisciplinarity in precision oncology to identify rare, disease-defining genotypes that make an otherwise difficult-to-treat disease targetable.
Asunto(s)
Neoplasias , Proteínas Tirosina Quinasas , Femenino , Humanos , Adulto , Proteínas Tirosina Quinasas/genética , Calidad de Vida , Proteínas Proto-Oncogénicas/genética , Medicina de Precisión , Proteínas Tirosina Quinasas Receptoras/genética , Proteínas de Transporte VesicularRESUMEN
BACKGROUND: In MONALEESA-2, addition of ribociclib to letrozole resulted in significantly longer progression-free survival (PFS) in postmenopausal women with HR+HER2- advanced breast cancer (ABC). RIBociclib for the treatment of advanCed breast CAncer (RIBECCA) study investigated ribociclib plus letrozole in a patient population reflecting routine clinical practice. PATIENTS AND METHODS: In this multicenter, open-label, single-arm, phase 3b study, patients with HR+HER2- ABC not amenable to curative therapy and ECOG performance status ≤ 2 received ribociclib plus letrozole (cohort A: postmenopausal women and men in first-line; cohort B: pre-/perimenopausal women in first-line [B1], patients pretreated for advanced disease [B2]). The primary endpoint was clinical benefit rate (CBR) by week 24; secondary endpoints included overall response rate (ORR), PFS, overall survival (OS), and safety. Association of patient and tumor characteristics with PFS was analyzed by multivariable Cox regression analysis. RESULTS: Overall, 487 patients were evaluable for efficacy, 502 for safety. By week 24, CBR was 60.8 % (95 % CI, 56.3-65.1), ORR was 19.3 % (95 % CI, 15.9-23.1). Median PFS was 21.8 months (95 % CI, 13.9-25.3) in first-line postmenopausal patients and 11.0 months (95 % CI, 8.2-16.4) in premenopausal and pretreated patients. Median OS was not reached. Higher baseline ECOG performance status, higher histological grade, and negative progesterone receptor status showed an unfavorable effect on PFS. Most common adverse events were neutropenia (50.0 %), nausea (42.0 %), and fatigue (39.2 %). CONCLUSION: In this broad population of patients with HR+HER2- ABC, efficacy and safety results of ribociclib plus letrozole were similar to those observed in pivotal trials.
Asunto(s)
Neoplasias de la Mama , Purinas , Humanos , Femenino , Letrozol , Neoplasias de la Mama/patología , Receptor ErbB-2/metabolismo , Aminopiridinas/efectos adversos , Pronóstico , Inhibidores de la Aromatasa/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversosRESUMEN
Ruxolitinib (RUX) is a Janus kinase 1/2 inhibitor (JAKi) approved in the EU for treating diseaserelated splenomegaly or symptoms in adults patients with myelofibrosis (MF). This is an interim analysis of JAKoMo, a prospective, noninterventional, phase IV study in MF. Between 2012-2019 (cutoff March 2021), 928 patients (JAKi-naïve and -pretreated) enrolled from 122 German centers. This analysis focuses on JAKi-naïve patients. RUX was administered according to the Summary of Product Characteristics. Compared to the COMFORT-I, -II, and JUMP trials, patients in JAKoMo were older (median 73 years), had poorer Eastern Cooperative Oncology Group (ECOG) performance statuses (16.5% had ECOG ≥ 2), and were more transfusion dependent (48.5%). JAKoMo represents the more challenging patients with MF encountered outside of interventional studies. However, patients with low-risk International Prognostic Scoring System (IPSS) scores or without palpable splenomegaly were also included. Following RUX treatment, 82.5% of patients experienced rapid (≤ 1 month), significant decreases in palpable spleen size, which remained durable for 24 months (60% patients). Symptom assessment scores improved significantly in Month 1 (median -5.2) up to Month 12 (-6.2). Common adverse events (AEs) were anemia (31.2%) and thrombocytopenia (28.6%). At cutoff, 54.3% of patients had terminated the study due to, death, AEs, or deterioration of health. No new safety signals were observed. Interim analysis of the JAKoMo study confirms RUX safety and efficacy in a representative cohort of real-world, elderly, JAKi-naïve patients with MF. Risk scores were used in less than half of the patients to initiate RUX treatment.Trial registration: NCT05044026; September 14, 2021.
Asunto(s)
Inhibidores de las Cinasas Janus , Mielofibrosis Primaria , Adulto , Humanos , Anciano , Esplenomegalia/tratamiento farmacológico , Mielofibrosis Primaria/diagnóstico , Mielofibrosis Primaria/tratamiento farmacológico , Estudios Prospectivos , Nitrilos , Resultado del TratamientoRESUMEN
BACKGROUND: Eribulin, a halichondrin-class microtubule dynamics inhibitor, is a preferred treatment option for patients with advanced breast cancer who have been pretreated with an anthracycline and a taxane. Peripheral neuropathy (PN) is a common side effect of chemotherapies for breast cancer and other tumors. The Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) noninterventional postauthorization safety study assessed the incidence and severity of PN in patients with breast cancer treated with eribulin. PATIENTS AND METHODS: IRENE is an ongoing observational, single-arm, prospective, multicenter, cohort study. Adult patients (≥18 years of age) with locally advanced or metastatic breast cancer and disease progression after 1-2 prior chemotherapeutic regimen(s) for advanced disease were treated with eribulin. Patients with eribulin-induced PN (new-onset PN or worsening of preexisting PN) were monitored until death or resolution of PN. Primary endpoints included the incidence, severity, and time to resolution of eribulin-induced PN. Secondary endpoints included time to disease progression and safety. RESULTS: In this interim analysis (data cutoff date: July 1, 2019), 67 (32.4%) patients experienced any grade eribulin-induced PN, and 12 (5.8%) patients experienced grade ≥3 eribulin-induced PN. Median time to resolution of eribulin-induced PN was not reached. Median time to disease progression was 4.6 months (95% CI, 4.0-6.5). Treatment-emergent adverse events (TEAEs) occurred in 195 (93.8%) patients and serious TEAEs occurred in 107 (51.4%) patients. CONCLUSION: The rates of any grade and grade ≥3 eribulin-induced PN observed in this real-world study were consistent with those observed in phase III randomized clinical trials. No new safety findings were observed.
Asunto(s)
Neoplasias de la Mama , Enfermedades del Sistema Nervioso Periférico , Adulto , Femenino , Humanos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Estudios de Cohortes , Progresión de la Enfermedad , Furanos/efectos adversos , Incidencia , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Enfermedades del Sistema Nervioso Periférico/epidemiología , Estudios Prospectivos , Resultado del Tratamiento , Moduladores de Tubulina/efectos adversosRESUMEN
Rotating MRI systems could enable novel integrated medical devices such as MRI-Linacs, MRI-xray-angiography systems, and MRI-proton therapy systems. This work aimed to investigate the feasibility of rotating actively shielded superconducting MRI magnets in the presence of environmental steel-in particular, construction steel in the floor of the installation site. Two magnets were investigated: a 1.0 T split bore magnet, and a 1.5 T closed bore magnet. Each magnet was scaled to emulate field strengths of 0.5, 1.0, and 1.5 T. Finite Element Modeling was used to simulate these magnets in the presence of a 3 × 4 m steel plate located 1250 mm or 1400 mm below the isocenter. There are two possible rotation directions: around the longitudinal (z) axis or around the transverse (x) axis. Each model was solved for rotation angles between 0 and 360° in 30° intervals around each of these axes. For each simulation, a 300 mm DSV was extracted and decomposed into spherical harmonics. For the closed-bore magnet, total induced perturbation for the zero degree rotation angle was 223, 432, and 562 µT peak-to-peak (pk-pk) for the 0.5, 1.0, and 1.5 T models respectively (steel at 1250 mm). For the split-bore magnet, the same numbers were 1477, 16747, and 1766 µT. The substantially higher perturbation for the split-bore magnet can be traced to its larger fringe field. For rotation around the z-axis, total perturbation does not change as a function of angle but is exchanged between different harmonics. For rotation around the x-axis, total perturbation is different at each rotation angle. For the closed bore magnet, maximum perturbations occurred for a 90° rotation around the transverse axis. For the split-bore magnet, the opposite was observed, with the same 90° rotation yielding total perturbation lower than the conventional position. In all cases, at least 95% of the total perturbation was composed of 1st and 2nd order harmonics. The presence of environmental steel poses a major challenge to the realization of an actively shielded rotating superconducting MRI system, requiring some novel form of shimming. Possible shimming strategies are discussed at length.
Asunto(s)
Imagen por Resonancia Magnética/métodos , Imanes , Modelos Teóricos , Acero , Aceleradores de Partículas , RotaciónAsunto(s)
Inmunoterapia/métodos , Neoplasias/tratamiento farmacológico , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Células Presentadoras de Antígenos/inmunología , Linfocitos T CD8-positivos/inmunología , Antígeno CTLA-4/antagonistas & inhibidores , Muerte Celular , Células Dendríticas/inmunología , Inmunoterapia/efectos adversos , Ipilimumab/uso terapéutico , Ganglios Linfáticos/inmunología , Neoplasias/inmunología , Receptor de Muerte Celular Programada 1/fisiología , Receptores de Antígenos de Linfocitos T/inmunología , Resultado del TratamientoAsunto(s)
Antineoplásicos/efectos adversos , Esperanza , Conducta de Enfermedad , Neoplasias/diagnóstico , Neoplasias/psicología , Antineoplásicos/uso terapéutico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/psicología , Humanos , Neoplasias/tratamiento farmacológico , PronósticoAsunto(s)
Antineoplásicos/efectos adversos , Conducta de Enfermedad , Neoplasias/terapia , Educación del Paciente como Asunto/tendencias , Adulto , Anciano , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/psicología , Neoplasias de la Mama/terapia , Carcinoma Ductal de Mama/psicología , Carcinoma Ductal de Mama/terapia , Quimioterapia Adyuvante/efectos adversos , Quimioterapia Adyuvante/psicología , Terapia Combinada/efectos adversos , Terapia Combinada/psicología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/psicología , Femenino , Alemania , Humanos , Neoplasias Pulmonares/psicología , Neoplasias Pulmonares/terapia , Linfoma de Células B Grandes Difuso/psicología , Linfoma de Células B Grandes Difuso/terapia , Masculino , Terapia Neoadyuvante/efectos adversos , Terapia Neoadyuvante/psicología , Neoplasias/psicologíaAsunto(s)
Infecciones por Papillomavirus/diagnóstico , Lesiones Precancerosas/diagnóstico , Neoplasias Cutáneas/diagnóstico , Adulto , Neoplasias del Ano/diagnóstico , Niño , Condiloma Acuminado/diagnóstico , Femenino , Humanos , Masculino , Neoplasias de Oído, Nariz y Garganta/diagnóstico , Neoplasias del Cuello Uterino/diagnósticoRESUMEN
Castration-resistant prostate cancer (CRPC) is partially characterised by overexpression of antiapoptotic proteins, such as survivin. In this phase 2 study, patients with metastatic CRPC (n=154) were randomly assigned (1:2 ratio) to receive standard first-line docetaxel/prednisone (control arm) or the combination of LY2181308 with docetaxel/prednisone (experimental arm). The primary objective was to estimate progression-free survival (PFS) for LY2181308 plus docetaxel. Secondary efficacy measures included overall survival (OS), several predefined prostate-specific antigen (PSA)-derived end points, and Brief Pain Inventory (BPI) and Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores. The median PFS of treated patients for the experimental arm (n=98) was 8.64 mo (90% confidence interval [CI], 7.39-10.45) versus 9.00 mo (90% CI, 7.00-10.09) in the control arm (n=51; p=0.755). The median OS for the experimental arm was 27.04 mo (90% CI, 19.94-33.41) compared with 29.04 mo (90% CI, 20.11-39.26; p=0.838). The PSA responses (≥ 50% PSA reduction), BPI, and FACT-P scores were similar in both arms. In the experimental arm, patients had a numerically higher incidence of grades 3-4 neutropenia, anaemia, thrombocytopenia, and sensory neuropathy. In conclusion, this study failed to detect a difference in efficacy between the two treatment groups.